Lumida
/ILMN
⌘K
Illumina Inc

Illumina Inc

ILMN
$206.45USD+2.57%+5.18 today

MARKET CAP

31.2B

P/E (TTM)

37.5x

FWD P/E

DAY RANGE

$200 – $208

52W RANGE

$88
$232

AI Summary

Stalk
TrimMedium

ILMN is exhibiting persistent lower highs and lower lows, confirming a medium-term bearish bias despite a longer-term uptrend. Price is currently testing the 50-day SMA support zone with 9- and 20-day EMAs overhead acting as resistance. Short-term timing remains unfavorable for a bearish entry until a bounce into the EMA resistance area provides a clear rejection. A deferred sell (trim) into the $209–$210 resistance zone is advised.

  • Q2 2026 revenue reached $1.16B (+9.5% YoY) on 15% clinical consumables growth
  • Non-GAAP operating margin 22.5% and gross margin 68.2%, with 150 bp sequential expansion guided
  • Research revenues may fall mid-to-high single digits amid NIH funding uncertainty
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2023FY 2024FY 2025TREND
Sales, Adj.$4.5B$4.5B$4.5B$4.4B$4.3B
YoY %+39.7%-1.7%-1.7%-2.9%-0.7%
P / Sales12.7x4.8x4.8x4.9x4.8x
EV / Sales13.4x5.6x5.6x5.5x5.4x
Gross Profit, Adj.$3.2B$2.7B$2.7B$2.9B$2.9B
YoY %+43.2%-7.7%-7.7%+4.3%+0.3%
Margin %69.7%60.9%60.9%65.4%66.1%
EV / Gross Profit19.3x9.1x9.1x8.4x8.2x
EBITDA, Adj.$128.0M$210.0M$210.0M$954.0M$1.1B
YoY %-83.3%-71.9%-71.9%+354.3%+13.9%
Margin %2.8%4.7%4.7%21.8%25.0%
EV / EBITDA474.7x119.3x119.3x25.2x21.6x
EBIT$-123.0M$-1.1B$-1.1B$-833.0M$807.0M
YoY %-121.2%+74.4%+74.4%+22.1%+196.9%
Margin %-2.7%-23.7%-23.7%-19.1%18.6%
EV / EBIT-494.0x-23.4x-23.4x-28.9x29.1x
Net Income$762.0M$-1.2B$-1.2B$-1.2B$850.0M
YoY %+16.2%+73.6%+73.6%-5.3%+169.5%
Net Margin16.8%-25.8%-25.8%-28.0%19.6%
EPS (GAAP)$5.04-$7.34-$7.34-$7.69$5.45
YoY %+13.3%+73.8%+73.8%-4.8%+170.9%